Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage

Sci Adv. 2023 Dec 22;9(51):eadg7545. doi: 10.1126/sciadv.adg7545. Epub 2023 Dec 20.

Abstract

We report on the identification of extracellular miRNA (ex-miRNA) biomarkers for early diagnosis and prognosis of preeclampsia (PE). Small RNA sequencing of maternal serum prospectively collected from participants undergoing evaluation for suspected PE revealed distinct patterns of ex-miRNA expression among different categories of hypertensive disorders in pregnancy. Applying an iterative machine learning method identified three bivariate miRNA biomarkers (miR-522-3p/miR-4732-5p, miR-516a-5p/miR-144-3p, and miR-27b-3p/let-7b-5p) that, when applied serially, distinguished between PE cases of different severity and differentiated cases from controls with a sensitivity of 93%, specificity of 79%, positive predictive value (PPV) of 55%, and negative predictive value (NPV) of 89%. In a small independent validation cohort, these ex-miRNA biomarkers had a sensitivity of 91% and specificity of 57%. Combining these ex-miRNA biomarkers with the established sFlt1:PlGF protein biomarker ratio performed better than either set of biomarkers alone (sensitivity of 89.4%, specificity of 91.3%, PPV of 95.5%, and NPV of 80.8%).

MeSH terms

  • Biomarkers
  • Female
  • Humans
  • MicroRNAs* / genetics
  • Pre-Eclampsia* / diagnosis
  • Pre-Eclampsia* / genetics
  • Pregnancy
  • Prognosis
  • Triage
  • Vascular Endothelial Growth Factor Receptor-1

Substances

  • MicroRNAs
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1
  • Biomarkers
  • MIRN522 microRNA, human